belantamab mafodotin   Click here for help

GtoPdb Ligand ID: 11117

Synonyms: belamaf [4] | belantamab mafodotin-blmf | Blenrep® | GSK-2857916 | GSK2857916
Approved drug Immunopharmacology Ligand
belantamab mafodotin is an approved drug (FDA & EMA (2020))
Compound class: Antibody
Comment: Belantamab mafodotin (GSK2857916) is a humanised BCMA-targeting antibody-drug conjugate that is in clinical development for multiple myeloma. Mafodotin is the cytotoxic, synthetic antineoplastic monomethyl auristatin F (MMAF; PubChem CID 56841603). Belantamab mafodotin is an IgG1 class antibody so, in addition to its delivery of a cytotoxin, it is predicted to exhibit lytic activity (through complement binding) and/or induce antibody-dependent cell cytotoxicity (ADCC). GlaxoSmithKline claim anti-BCMA ADCs in patent US9273141B2 [1]. SEQ IDs 55 and 63 from US9273141B2 match the full-length heavy chain and light chain sequences respectively, that were submitted to the WHO for the belantamab mafodotin INN.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Immunopharmacology Comments
Belantamab mafodotin (GSK2857916) targets a cytotoxic payload to abnormal immature plasma MM cells that express the B cell maturation antigen (BCMA: TNFRSF17). One notable side-effect of belantamab mafodotin that has not been observed with other multiple myeloma drugs is keratopathy (a corneal condition that causes dry eyes, blurry vision and potentially, severe vision loss) [5]. GlaxoSmithKline are advising using a risk evaluation and mitigation strategy to manage this adverse reaction, that includes eye examinations before each treatment cycle and reducing or delaying the next dose if appropriate.